Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial
The survival benefit of enzalutamide compared with placebo in men with progressive castration-resistant prostate cancer after prior docetaxel-based chemotherapy is accompanied by stabilization of patient HRQoL, as assessed by FACT-P. Application of different analytic methods to the FACT-P data furth...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Oxford University Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269344/ |